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Successful management of laboratory robotic automation pro-
grammes in the environment of research and drug discovery within
thepharmaceutical industry mayperhaps be best compared to a chef
preparing the perfect hollandaise sauce. All the ingredients must be
available at the same time and be of highest qualityfor the right
price. However, ifcomponents are notadded in the right quantities
and in the proper order, no amount of whipping together by the
product champion will create the best product. In the past,
managerial scepticism surrounding useful implementation of cost-
effective, high-throughput robotic systems often placed these
’modern toys’ at low priorities for research development labora-
tories. Management now recognizes the unique contributions of
robotics in the research environment. Although the scientific director
must still play the role ofproduct champion, new questions are
being proposed and new commitments are being made to bring the
potential of robotic automation to every laboratory where repetitive
functions can benefit from new applications. Research laboratory
directors have become both the key ingredient, as well as the rate-
limiting determinant in the development of new applications.
Having fulfilled the promise of robotic automation to release
talentedpersonnel, the challenge now isfor the ’end users’, the bench
scientists, to be provided with opportunities to invest the time and
effort requiredforfuture applications and new careerfunctions.
We saw him sit and try to cook.
He took a look at the book on the hook.
But a Nook can’t read, so a Nook can’t cook.
so what good to a Nook is a hook cook book?
Every day from here to there, funny things are
everywhere.
DrSeuss [1]
Why was a biochemist involved in drug discovery in areas
of cholesterol metabolism and heart disease at the
podium in the early morning hours to present a keynote
address to several hundred sleepy robotics specialists?
What is the relevance to robotics scientists ofa dedication
to Dr Seuss’ famous character who could not cook?
It was not the wrong time or place for the lecture-
although one might have argued that biologists have been
missing from International Robotics meetings and this
discussion should have happened years earlier! Research
biologists have been like the Nook when it comes to the
use of robotics as a research tool- ifyou don’t see or can’t
read about it, it may not exist. This is surprising and
distressing at the same time, since many advances in
current drug development efforts in the pharmaceutical
industry already pay homage to automated equipment
and advanced computer-assisted robotic operations.
These systems are in use and provide more efficient and
economical use for resources in late-stage drug formula-
tion, stability and chemical analysis activities. The same
basic elements have been available to the biologists at the
front end ofdrug discovery, but little published literature
describes any major conceptual or research advance in
the use ofrobotics made in these laboratory settings. With
the considerable investment that a pharmaceutical com-
pany makes in R&D, one should expect there to be state-
of-the-art equipment and automation capabilities in
every phase of drug development. Ifwe accept the reality
that biologist and research managers have been slow to
adapt robotics to their research automation concepts,
there must be simple reasons for this problem that can be
considered before we run out of time in the twentieth
century.
The average academic and pharmaceutical biologist and
research manager may still consider laboratory robotics
to be in the same ’magical’ category as the robots of Isaac
Asimov’s novel or the Hollywood screen image ofWoody
Allen hiding in disguise as a robot butler in the movie
’Sleeper’. The average library has a wealth of infor,-
mation, books and magazines which preview the ’glitzy’
consumer-oriented potential values of robots that play
piano, make sushi and pizza, etc. [2,3]. How many
university or pharmaceutical libraries have as much
information devoted to robotics?
At Sandoz Research Institute, an opportunity was
created for biologists to develop a drug discovery
programme using robotic microplate management
systems as analysis tools. This programme was accom-
plished with minimum amounts of funding and a staff of
no more than two over a two-year period; but required an
extensive learning process, as well as education of our
senior research directors. Our process for adding a
robotics component to a disease-oriented drug discovery
process was not much different than that used by a cook
making a classic hollandaise sauce or mayonnaise.
Mayonnaise is a simple mixture of protein and fats and
oils from eggs or other sources which when blended or
whipped properly forms a stable emulsion which traps
water and flavour ingredients [4]. In the research world,
the key issues are to have available all the right
ingredients (creative people + good, simple ideas + a
little bit of fantasy + attainable goals) and add them
together in the right quantities and the right order under
the direction of the most important ingredient: the
product champion. The role of the research director who
is the product champion is to blend together the research
and personnel components with the creative environment
provided by management in order to create the successful
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Figure 1. Activity profile of bench scientists in 1987.
and stable integration of robotics into the early stages of
drug discovery. Thus, the chef making mayonnaise, and
the research manager putting together a robotic research
programme, require reasonably similar steps to produce
the best product.
What are the components of the mayonnaise which make
up the typical efforts of new drug-discovery processes
within the pharmaceutical .industry today? A major
component is the effective team effort of both biologist
and medicinal chemists in a specifically ordered sequence
as a programme begins. First, the team must determine
the biological site or mechanism of action which is the
target of the new drug substance. Second, there must be
developed a set ofin vitro and in vivo test models, which can
discriminate between compounds which effectively alter
the biological target selected. Third, large numbers of
medicinal chemists would provide rational concepts
towards design of complicated chemical molecules which
alter the biological regulatory mechanism selected as the
drug target. This rational chemical design concept is
often balanced by a well-known pharmaceutical pro-
gramme called ’random-screening’ in which complex
biological samples from natural sources such as bacterial
and fungal broths, extracts from plants, natural herbal
remedies etc. are screened through assays to measure
effects on cell growth, enzyme activities or complex
biological behaviours. The roots of the pharmaceutical
development of drugs lie in this ancient and tedious
method of searching through natural products.
It has been estimated that one major new biological lead
will result from 20-50 000 random screening analyses,
providing that the analysis has the proper discriminating
power for separating positive and false-positive or
negative hits. One would like to screen a minimum of
50 000 samples a year through the appropriate assay
screens in order to have a high enough rate of new lead
acquisition for new programmes in drug discovery. One
can readily identify the need for robotic screening and
analysis in this process, which a single screening pro-
gramme in one disease area requires such high through-
put of repetitive sample preparation and analysis. Even
with this type of biological lead in hand, it may still take
several years of chemical modification and supportive
biological and toxicological development before a .drug
may appear on the market.
A substantial commitment of effort of many skilled staff
members is required for successful completion and
development of drug discovery functions. An analysis of
the activity profile of Sandoz’s biology bench scientist for
the year 1987 is shown in figure 1. New assay develop-
ment for research screening and analysis accounted for
approximately one third of biology staff time at the lab
bench. Additionally, despite the widespread use of
modern computer hardware and software it required just
over 50% of the scientist’s time to compile, analyse,
manage, and report the data accumulated by all analysis
systems. Only 15% of their time was devoted to staffand
scientific meetings. However, in this pre-robotics era, our
technical staff had little or no free time for new training
opportunities and other creative growth programmes.
Further analysis of the research programme indicated
that several constant parameters, or requirements, could
be deduced from the standard operating practices which
defined the operations of good drug screening. First,
amongst these parameters, is the requirement for a high
degree of precision of measurements. Second, is the
requirement that a robust assay be reproducible over long
periods oftime during the search for active agents. Third,
is that the assay be able to discriminate between weakly-
effective, as well as, strongly active compounds. Finally,
the assay must have a high enough throughput to allow
for a low ’hit-rate’ at the early stages of development of
any screen. All of these parameters were ideally suited for
robotic development of new screening programmes
Figures 2 and 3 shows typical examples of the, analysis
methods which have been developed in Sandoz’s lipopro-
tein laboratory. The first (figure 2) is a serum cholesterol
analysis indicating the excellent linear correlation
between the final robotic assay and the manual assay
from which it was developed. Figure 3 shows the
consistency of performance of the assay over three years
using four cholesterol reference standards. As a conse-
quence of the introduction of two robots to perform a
number of varied analytical end-points, this laboratory
has experienced a continuing increase in the number of
new chemical entities screened per year since 1988 (figure
4). In 1991, time spent by the staff on new assay
development continued to increase (32% to 40%);
however, analysis and data management time has
dropped from 54% to only 10% of total effort (figure 5).
Thus, 50% of total staff time is now available for new,
more creative functions, managerial, training and pro-
fessional activities. On the lighter side, as management
has been exposed to the successful development of
robotics within our research laboratory environment
there had been a corresponding linear increment in the
number of laboratory tours given for visiting dignitaries
and consultants (figure 6).
In the past, managerial scepticism surrounding useful
implementation of cost-effective, high-throughput
robotic systems often placed these ’modern toys’ at low
priorities for research and development laboratories.
Robotics, at the level of the research laboratory, has
different rationales and constraints than does heavy
industry robotization. For the research or clinical labora-
tory there is the necessity to maintain repetitive analysis
of biological samples, which is most often conducted by
highly skilled technical staff. Efficiency of function tends
to fall and errors in analysis tend to increase in proportion
to the fatigue and tedium introduced by the constant need
for repetition. Coupled with the need for higher through-
put in front-end biological research screening are the
dynamic changes in team management concept and
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Figure 4. Robotic automation increases number of compounds
screened.
Figure 3. Performance of quality control standards over time.
managerial approaches in many industrial settings.
Management now recognizes the unique contribution of
robotics in the research environment, which can allow
highly skilled team members to pursue more creative
functions than those programmes which may have
committed these staffmembers to be tied to performance
of manual repetitive tasks.
It has been suggested that Japanese industrial managers
and government officials consider robots to be an
essential component of industrial growth in a nation
which has a severe labour shortage problem, com-
pounded by limitations in Japan’s immigration policy
[2]. An opposite philosophy has existed in a number of
US industrial markets in which robotic automation has
been considered to be a threat to jobs that might be more
appropriately or successfully accomplished by modern
NSt ASSAY DEVELOPMENT
40.0g
MANA FUNtONS
15.0
SCIENTIFIC MEgrINGS
15.0
20.0
ANALYS & DATA MANA(ENT
10.0
Figure 5. Activity profile of bench scientist in 1991.
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Figure 6. Robotic systems increase number of laboratory tours.
engineering rather than by creative staffing. Are we doing
things correctly in adapting robotic and automation to
the drug research and development functions of the
pharmaceutical industry? Robotic technology occurs in
companies of all sizes in Japan, while in the US the
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market appears to be left exclusively to a relatively small
number of the major manufacturing industries. As the
robot gap widens, the monetary investment inJapan is at
a level at least six time that of US industrial investment
[2], fewer industrial robots are at work in the US than the
number of new robots added last year alone in Japan.
Japanese robotic companies expect that one or more
robots will be at work in everyJapanese house in the 21st
century.
While efforts to increase productivity have been the early
driving force behind robotic automation, current motiva-
tion tends to develop from the scientific curiosity of
exploring other planets or placing robots in environments
which are hazardous to human workers for extended
periods [5]. In the biological arena, it has been suggested
that hospital clinical laboratories will become the site of
significant growth of laboratory robotics in an effort to
solve the medical technologist shortage and escalating
costs of laboratory analysis [6]. A number of papers
published within the past year highlight biological
research applications which have been partially or
completely adapted to robotic automation systems in the
clinical laboratory setting. To solve staffing problems,
and protect technologists from handling potentially
hazardous human blood samples, the Kochi Medical
School Department of Clinical Laboratory Medicine
developed assays for eight hormones measured sequen-
tially from human blood [7]. While the robot incubates
samples at six different time intervals for the eight assays
it performs many ofthe wash and reagent addition cycles.
Not only does the staff avoid contact with blood, but the
investigators conclude ’the robot is considered useful and
indispensable for routine jobs’. Similar reports on robo-
tics automated blood analysis routines [8] highlight the
increased handling safety, optimization of smallest sam-
ple size for high throughput, flexible, serial ordering of
tests, and increased quality control of data and patient
identification. An interesting example of increased
efficiency and throughput can be obtained in a series of
comparative case studies by Ciba-Corning Diagnostics
[9] reviewing five studies of hospital and reference
laboratories to determine whether semi-automated
immunochemical analyses could be enhanced by robotics
systems. It was determined that reduction in labour costs
(33-67%), and reduced turnaround time for samples
occurred in all laboratories irrespective of the size of the
programme with payback for the robotics systems
occurring within one year in four of the five laboratories.
In the past year, a number of robotic applications have
appeared in the molecular biology literature. Examples
range from automation of gene expression of easily
assayed enzymes, such as bacterial chloramphenicol
acetyltransferase (CAT) using kinetic monitoring of the
enzymatic reaction, and elimination of the chromato-
graphic separations required in the original published
method [10]. Automated detection of specific DNA
sequences for both diagnostic evaluation and determi-
nation of genetic polymorphism are now becoming more
numerous [11]. The applications of robotics in this field
are potentially only limited by the imagination and skill of
the investigators.
Robots are now being used in nearly every phase of drug
development within the pharmaceutical, industry. It is
unfortunate that the bounds of proprietary information
does not permit industrial scientists to share their
experiences in robotic development, such as in appli-
cation of general screening of discovery of new drug
substances. An excellent example of the design strategy
and benefits ofautomation ofdrug testing can be found in
a new National Cancer Institute human tumour drug
screen [12]. The original screening assay in mice was
extremely labour intensive and was poorly predictable to
human disease. After NCI switched to a screen of 60
different human cancer cells in cell culture, an automated
microplate assay system was developed which achieved a
greater than tenibld increase in productivity over manual
methods for only twice the total cost. Robotic automation
has increased the capacity to screen over 40 000 com-
pounds per year at approximately 20% of the cost per
compound in the original manual assay.
Despite the improved efficiency and increased through-
put with" short payback times for return on investment
costs, there are still sceptics who suggest that robotic
automation has limited application to clinical and
research laboratories. These analyses often argue that the
speed ofindividual operations ofa robot is slow compared
to that of manual methods. This is certainly true;
however, on the basis of continuous operation for
extended time periods of up to 24 h per day the robotic
systems are undoubtedly more accurate and precise than
technicians performing the same functions in a repetitive
manner over a 6-8 h work shift. A key ingredient in the
successful application of robotics to research laboratory
problems is the integration of research staff expertise
design of scanning assays which can be coupled with the
engineering skills atd hardware development capabilities
of robotics development companies. The product of this
interaction can be simpler and faster robotic operations
which can be done in combination with precision batch
technology- such as in the microplate technology used at
the Sandoz Research Institute- with appropriate flexi-
bility to achieve best quality and highest throughput. We
must also keep in mind that it is not always practical or
essential to robotize every step or procedure in a complex
series of sample preparation or analysis. In the simplest
case, the chef’s list of ingredients for successful develop-
ment should include:
(1) Creative research staff support.
(2) Co-operative engineers.
(3) Simple movements for robots.
(4) Precise movement of individual steps.
(5) Constant sample history.
(6) Flexibility of combinations of operations.
The largest asset which may be acquired through robotic
automation in the environment ofthe research laboratory
can be the creative re-investment of the talent of the
people who can be freed from the tedium of continuously
repetitive research operations. A goal of every research
laboratory director should be to provide growth and
opportunity for all staff members. To this end, one can
expand the opportunities of the ’cooks’ at the laboratory
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bench by blending together the ingredients of laboratory
robotic automation with well-co-ordinated team efforts of
the laboratory staff.
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